DaVita Inc. vs Dr. Sulaiman Al Habib Medical S
A head-to-head of DaVita Inc. (DVA) and Dr. Sulaiman Al Habib Medical S (4013) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | DVA | 4013 |
|---|---|---|
| Market Cap | $15.21B | 75.29B SAR |
| P/E (TTM) | 21.98 | 31.36 |
| Forward P/E | 11.63 | 28.64 |
| P/S | 0.91 | 5.45 |
| P/B | 15.64 | 9.47 |
| EV/EBITDA | 8.90 | 26.07 |
| Dividend Yield | — | 1.85% |
| Profit Margin | 5.65% | 16.79% |
| Gross Margin | 32.25% | 30.69% |
| Operating Margin | 14.74% | 19.26% |
| Revenue Growth (YoY) | +5.96% | +8.80% |
| FCF Yield | 12.00% | 0.81% |
| Debt / Equity | 1013.79 | 113.79 |
| Current Ratio | 1.42 | 1.14 |
Which is better: DaVita Inc. or Dr. Sulaiman Al Habib Medical S?
- ✓Larger by market cap: Dr. Sulaiman Al Habib Medical S
- ✓Cheaper valuation (lower P/E): DaVita Inc.
- ✓More profitable (net margin): Dr. Sulaiman Al Habib Medical S
- ✓Faster revenue growth: Dr. Sulaiman Al Habib Medical S
- ✓Higher free-cash-flow yield: DaVita Inc.
Across 12 available metrics, DaVita Inc. leads 7–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.